Article: AEterna Zentaris: New Data Published on its Ghrelin Antagonist Compound, AEZS-123 (JMV2959), Supports its Use in Alcohol Addiction.

Data published in July 7, 2009 Issue of Proceedings of the National Academy of Sciences

QUEBEC CITY, July 7 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication in the renowned American scientific journal, Proceedings of the National Academy of Sciences (PNAS), of new data supporting the use of AEterna Zentaris' ghrelin receptor antagonist compound, AEZS-123 (JMV2959), for the treatment of alcohol dependence that involves ghrelin. Ghrelin is a hormone produced by the stomach and acting in the brain. Compelling evidence obtained with the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!